Clinical Study | Office of Clinical Research

Viela Bio A Randomized, Double-Blind, Multicenter,Placebo-Controlled Phase 3 Study With Open-Label Period To Evaluate The Efficacy And Safety Of Inebilizumab In Adults With Myasthenia Gravis

Posted Date: Mar 5, 2021

Investigator: Hani Kushlaf
Specialties:
Type of Study: Drug

Randomized, double-blind, placebo-controlled, parallel-group study with optional open-label extension

Criteria:

Adult Subjects Aged = 18 Years With Acetylcholine Receptor Antibody Positive (Achr-Ab+) Or Muscle-Specific Kinase-Antibody Positive (Musk-Ab+) Generalized Mg

Keywords:

For More Information:

Elizabeth Gehlmann
513-558-4497
gehlmaem@ucmail.uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List